[Aspirin and cardiovascular prevention: last minute information]

Area of Science:

• Gastroenterology
• Cardiology
• Pharmacology

Background:

• Aspirin is widely used for cardiovascular prevention, but carries a risk of gastrointestinal (GI) bleeding, particularly in patients with a history of ulcers.
• Clopidogrel is often recommended as an alternative for patients intolerant to aspirin, especially those with a history of ulcer bleeding.
• Managing GI risks while maintaining cardiovascular protection is a critical clinical challenge.

Purpose of the Study:

• To compare the efficacy of aspirin plus esomeprazole versus clopidogrel in preventing recurrent ulcer bleeding in patients with a history of aspirin-induced ulcers.
• To evaluate the safety and effectiveness of combined aspirin-esomeprazole therapy in a high-risk patient population.

Main Methods:

• A randomized controlled trial involving 320 patients with healed ulcers and a history of ulcer bleeding while taking aspirin.
• Patients were assigned to receive either 75 mg of clopidogrel daily or 80 mg of aspirin daily plus 20 mg of esomeprazole twice daily.
• Follow-up was conducted over 12 months to monitor for recurrent ulcer bleeding.

Main Results:

• Recurrent ulcer bleeding occurred in 8.6% of patients receiving clopidogrel compared to 0.7% in the aspirin plus esomeprazole group.
• The difference in cumulative incidence of recurrent bleeding was statistically significant (p = 0.001).
• Only 1 patient in the aspirin-esomeprazole group experienced recurrent bleeding, versus 13 in the clopidogrel group.

Conclusions:

• Combining low-dose aspirin with a proton pump inhibitor like esomeprazole is significantly more effective in preventing recurrent ulcer bleeding than clopidogrel in patients with a history of aspirin-induced ulcers.
• Current recommendations suggesting clopidogrel as a preferred alternative for aspirin-intolerant patients with a history of GI bleeding may need re-evaluation.
• This study highlights the importance of considering combination therapy for high-risk patients requiring antiplatelet medication.